RATIONALE-208: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Tislelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms RATIONALE-208
- Sponsors BeiGene
- 10 Apr 2018 According to a BeiGene media release, the first patient was dosed in this trial.
- 10 Apr 2018 Status changed from not yet recruiting to recruiting, as reported in a BeiGene media release.
- 07 Feb 2018 New trial record